Indomethacin (GMP)

Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research^[1][2][3]. In Vitro:Indomethacin (Indometacin) (0-150 μM; 24 h; 3LL-D122 cells) has anticancer activity in vitro^[2].
Indomethacin (Indometacin) (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in elF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC₅₀=2μM)^[3].
Indomethacin (8 μM, 26 h) induces M1 to M2 macrophage reprogramming in RAW 264.7 cells^[4].
Indomethacin (200 μM, 5 d) induces the trans-differentiation of human adipose-derived stem cells into neurogenic cells^[5].
In Vivo:Indomethacin can be used in animal modeling to construct gastrointestinal ulcer models.

Indomethacin (Indometacin) (0.01-10 mg/kg; p.o.; for 3 hours; male Sprague-Dawley rats) induces paw oedema and hyperalgesmeasurement dose-dependently reversed carrageenan-induced hyperalgesia^[1].
Indomethacin (Indometacin) (10 mg/mL; p.o.; daily, for 29 days; male C57BL/6J mice) inhibits tumor growth in vivo^[2].